Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541069 | 0.89 | PDE4A (0.43) | CYP19A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL12540090 | 0.89 | PDE4A (0.43) | CYP19A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL12540092 | 0.89 | PDE4A (0.43) | CYP19A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL1515236 | 0.84 | HTR2C (0.47) | HDAC4HDAC2HDAC8PARP10NPC1 | |
| SCHEMBL29878889 | 0.84 | HTR2C (0.47) | HDAC4HDAC2HDAC8PARP10NPC1 | |
| SCHEMBL22350969 | 0.81 | ESR2 (0.47) | ESR2PARP10NPC1SCD5DRD4 | |
| SCHEMBL428343 | 0.81 | GAA (0.48) | CYP19A1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL353609 | 0.80 | HDAC4 (0.47) | HDAC4HDAC2HDAC8PARP10NPC1 | |
| SCHEMBL777204 | 0.80 | HDAC4 (0.52) | HDAC4HDAC2HDAC8PARP10NPC1 | |
| SCHEMBL30704252 | 0.80 | HDAC4 (0.52) | HDAC4HDAC2HDAC8PARP10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026047575-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250223276-A1 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-10 | — | — | US | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4543432-A1 | SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12281073-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-22 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | disclosed |
| EP-0588291-B1 | 2-Fluorobenzonitrile derivative | CHISSO CORP (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-5370822-A | Liquid crystals | CHISSO CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0588291-A1 | 2-Fluorobenzonitrile derivative | Chisso Corporation (JP) | 1994-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ESR2 846/4885HDAC4 720/4885HDAC2 733/4885 |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | ESR2 530/4885HDAC4 2380/4885HDAC2 2332/4885 |
| US-12281073-B2 | Substituted piperidine compound and use thereof | HCRTR2, HCRTR1, NTSR2 | ESR2 913/4885HDAC4 260/4885HDAC2 104/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | ESR2 3371/4885HDAC4 301/4885HDAC2 191/4885 |
| US-20250223276-A1 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | HCRTR2, HCRTR1, CNR2 | ESR2 2562/4885HDAC4 141/4885HDAC2 49/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | ESR2 609/4885HDAC4 654/4885HDAC2 431/4885 |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ZYX, PYM1, CPNE4 | ESR2 3315/4885HDAC4 4306/4885HDAC2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.